S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
SOUTH SAN FRANCISCO, Calif. - Senti Biosciences, Inc. (NASDAQ:SNTI), a clinical-stage biotechnology company with a market capitalization of $86 million, has recently released an animated video illustrating the mechanism of action (MoA) of its lead asset, SENTI-202. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.49, indicating its ability to fund ongoing research. SENTI-202 is a novel cell therapy candidate designed to selectively target and eliminate certain hematologic malignancies while sparing healthy cells.
The therapy employs a "Logic-Gated" gene circuit that targets CD33 or FLT3, which are expressed in approximately 95% of Acute Myeloid Leukemia (AML) patients, without affecting healthy hematopoietic stem cells. The treatment also includes an "OR Logic Gate" that kills leukemia blasts and leukemic stem cells, a "NOT Logic Gate" that protects healthy cells, and a calibrated release of IL-15 to enhance the therapy’s activity and persistence in the body.
Senti Bio is currently enrolling adult patients with relapsed or refractory CD33 and/or FLT3-expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202. The trial has shown positive preliminary results, with no dose limiting toxicities and a maximum tolerated dose not reached. Early data suggest a recommended Phase 2 dose, with some patients achieving a complete remission and measurable residual disease-negative status. The stock has shown strong momentum, gaining over 56% in the past six months, though InvestingPro analysis indicates the company is rapidly burning through cash reserves.
The company presented recent data at the American Association for Cancer Research (AACR) Annual Meeting 2025, demonstrating the potential of SENTI-202 as a first-in-class allogeneic off-the-shelf treatment for AML and myelodysplastic syndrome (MDS) patients. With an analyst target price of $12, significantly above current trading levels, market experts see substantial upside potential. Discover more detailed financial insights and 8 additional key ProTips by subscribing to InvestingPro.
Senti Biosciences aims to leverage its Gene Circuit platform to create cell and gene therapies with enhanced precision and control for incurable diseases. The company’s pipeline includes therapies engineered to target various tumor indications. While the company’s financial health score is rated as "FAIR" by InvestingPro, with more cash than debt on its balance sheet, analysts do not expect profitability in the current fiscal year.
The information in this article is based on a press release statement from Senti Biosciences. The company’s forward-looking statements are predictions based on current expectations and assumptions and are subject to risks and uncertainties. These statements should not be relied upon as guarantees of future performance.
In other recent news, Senti Biosciences has reported encouraging preliminary results from its Phase 1 clinical trial of SENTI-202, a potential treatment for hematologic malignancies. The trial, which is ongoing, showed an overall response rate in five out of seven evaluable patients, with no dose-limiting toxicities observed. Financially, Senti Biosciences disclosed a net loss of $14.1 million for the first quarter of 2025, with cash reserves of approximately $33.8 million. Additionally, the company has appointed James B. Trager, Ph.D., to its Scientific Advisory Board, bringing extensive experience in cellular therapy development to the team. In a move to enhance shareholder communication, Senti Biosciences has joined Webull’s Corporate Connect Service, aiming to increase transparency and market visibility. Furthermore, the company announced the appointment of Feng Hsiung to its Board of Directors, along with the grant of stock options to new employees under its equity incentive plan. The company also announced changes to its Board and equity plans, including the resignation of Brenda Cooperstone from the Audit Committee and the approval of an amended equity incentive plan. These developments reflect Senti Biosciences’ ongoing efforts in advancing its clinical programs and strengthening its corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.